Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Microbix Biosystems Inc. T.MBX

Alternate Symbol(s):  MBXBF

Microbix develops proprietary biological technology solutions for human health and well-being, with about 90 skilled employees and sales growing from a base of over $1 million per month. It makes a wide range of critical biological materials for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs™) that support clinical lab proficiency testing, assay development and validation, or clinical lab workflows.


TSX:MBX - Post by User

Post by RazeKreationson Jan 05, 2023 1:49pm
311 Views
Post# 35205199

Microbix is in a better position than it has ever been

Microbix is in a better position than it has ever been Overall the Q4 results although being a little dissapointing those results were not a surprise.
There had been so little information for the last six months that, gave it away.
There is so much instability around the world with the high inflation and interest rates as well as the geopolitical scene between Russia and Ukraine as well as the growing threat  between China,USA and Taiwan wich brings a lot of concern for investors.
Microbix is in a very good position to weather these storms and survive.  Although 2022 was dissapointing they still made record income and grew cash balances as well as paying down debt, as well as improving control systems and equipment for future growth.
Much of the poorer than expected results came from the fact that customers have not gotten final regulatory approvals for the testing equipment that Microbix is going to supply then Qap's for. Which was a surprise expressed by Cameron.
When all the regulatory approvals are finished the qap's sales will pickup substantially. 
Cameron said that the first half of the year would be slow then it would pickup in the last half. If he was talking about the fiscal year, then we are into the second quarter now and end of March would end second quarter and the first half of the year.  
Kinlytic.................It drives me crazy, just because it has been promoted for over 20 years.  But it is beginning to look like it may finally have a chance to go forward with the shortage of Urokinaise around the worls and a growing demand.
Microbix is in a better position than it has ever been and is ready to take advantage of opportunities when they come.


<< Previous
Bullboard Posts
Next >>